The transaction was finalised following a definitive agreement signed by the companies in December 2023. Karuna now becomes a wholly owned BMS subsidiary.
Q&A: Increasing awareness around digital therapeutics key to realising full potential
Preview
来源: Pharmaceutical Technology
The US Food and Drug Administration (FDA) recently accepted a new drug application for KarXT for the treatment of adults with schizophrenia, with an approval decision anticipated on 26 September 2025 under the Prescription Drug User Fee Act.
“Importantly, this transaction aligns with our commitment to strengthening BMS’s growth profile in the latter half of the decade and beyond. We look forward to working with Karuna’s talented team to bring KarXT to patients with schizophrenia later this year.”